echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Youhe Pharmaceutical's Phase I clinical study of anti-4-1BB antibody in Australia completes the first patient administration

    Youhe Pharmaceutical's Phase I clinical study of anti-4-1BB antibody in Australia completes the first patient administration

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 7, Youhe Pharmaceuticals, a wholly-owned subsidiary of Biocytometer, announced that its YH004 (4-1BB monoclonal antibody) Phase I Australia (numbered YH004002) clinical study has completed its first patient administration


    This study is a classic multi-center, open-label, phase I dose-climbing study of YH004 single-agent and YH004 combined with anti-PD-1 monoclonal antibody.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.